SORRENTO THERAPEUTICS, INC. Form 8-K (Oct. 27, 2020)

Summary

Current report on Form 8-K for an event dated October 27, 2020, filed by Sorrento Therapeutics, Inc. Under Item 1.02, the report states that, effective October 27, 2020, the company voluntarily terminated a Common Stock Purchase Agreement dated April 27, 2020 with Arnaki Ltd. Under that agreement the purchaser had committed to purchase up to an aggregate of $250.0 million of the company's common stock over a 36-month term. The report states that the agreement was terminable at will by the company with no penalty. Henry Ji signed on October 27, 2020.

Summary drafted by a model from the document's text below and checked by script against that text before publication. It is a navigation aid, not a reading of what the document proves. Where AI is used

Cite this document

“SORRENTO THERAPEUTICS, INC. Form 8-K (Oct. 27, 2020).” Original at www.sec.gov. Archived at Pandemic Darlings, https://pandemicdarlings.com/source-documents/sec-srne-8-k-filed2020-10-27-0001104659-20-118549-4a6cba2821/, SHA-256 6b28397ea9f136f96b32b6e557abf0bea7be522f5a6ebc318b6be3c04e0bfd96.

Full text

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event
reported): October 27, 2020

SORRENTO THERAPEUTICS, INC.

(Exact Name of Registrant as Specified
in its Charter)

Delaware | 001-36150 | 33-0344842
(State or Other Jurisdiction of Incorporation) | (Commission File Number) | (IRS Employer Identification No.)

4955 Directors Place

San Diego , CA 92121

(Address of Principal Executive Offices)
(Zip Code)

Registrant’s telephone number,
including area code: ( 858 ) 203-4100

N/A

(Former Name, or Former Address, if Changed
Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities Registered pursuant to Section 12(b) of the Act:

Title of each class | Trading Symbol | Name of each exchange on which registered
Common Stock, $0.0001 par value | SRNE | The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ¨

If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 1.02. Termination of a Material
Definitive Agreement.

Effective October 27, 2020, Sorrento Therapeutics,
Inc. (the “Company”) voluntarily terminated that certain Common Stock Purchase Agreement (the “Purchase Agreement”),
dated April 27, 2020, by and between the Company and Arnaki Ltd. (the “Purchaser”). Pursuant to the Purchase Agreement,
the Purchaser had committed to purchase up to an aggregate of $250.0 million of shares of the Company’s common stock over
the 36-month term of the Purchase Agreement on the terms set forth therein. The Purchase Agreement was terminable at will by the Company with no penalty.

Item 9.01. Financial Statements and
Exhibits.

(d) Exhibit.

104 | Cover
Page Interactive Data File, formatted in Inline Extensible Business Reporting Language (iXBRL).

SIGNATURES

Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

SORRENTO THERAPEUTICS, INC.
Date: October 27, 2020 | By: | /s/ Henry Ji, Ph.D.
Name: Henry Ji, Ph.D.
Title: Chairman of the Board, President and Chief Executive Officer

File and source

File: SEC_SRNE_8-K_filed2020-10-27_0001104659-20-118549.htm
Size: 24,448 bytes
SHA-256: 6b28397ea9f136f96b32b6e557abf0bea7be522f5a6ebc318b6be3c04e0bfd96
Our copy: SEC_SRNE_8-K_filed2020-10-27_0001104659-20-118549.htm
Original: www.sec.gov